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Abstract
Background: The use of self-expanding metallic stents (SEMAS) in the treatment benign airway
obstruction is controversial.
Methods: To evaluate the safety and efficacy of SEMAS for this indication, we conducted a 10-year
retrospective review at our tertiary medical centre.
Results: Using flexible bronchoscopy, 82 SEMAS (67% Ultraflex, 33% Wallstent) were placed in 35
patients with inoperable lesions, many with significant medical comorbidities (88%). 68% of stents
were tracheal, and 83% of patients showed immediate symptomatic improvement. Reversible
complications developed in 9% of patients within 24 hrs of stent placement. Late complications
(>24 hrs) occurred in 77% of patients, of which 37% were clinically significant or required an
interventional procedure. These were mainly due to stent migration (12.2%), fracture (19.5%), or
obstructive granulomas (24.4%). The overall granuloma rate of 57% was higher at tracheal sites
(59%) than bronchial ones (34%), but not significantly different between Ultraflex and Wallstents.
Nevertheless, Wallstents were associated with higher rates of bleeding (5% vs. 30%, p = 0.005) and
migration (7% vs. 26%, p = 0.026). Of 10 SEMAS removed using flexible bronchoscopy, only one
was associated with incomplete removal of fractured stent wire. Median survival was 3.6 ± 2.7
years.
Conclusion: Ill patients with inoperable lesions may be considered for treatment with SEMAS.
Background
The role of stent placement for the treatment of benign
airway obstruction is still being fully elucidated. On July
29, 2005, the US Food and Drug Administration (FDA)
issued a Public Health Notification recommending
against the use of both covered and uncovered self-
expanding metallic tracheal stents (SEMAS) for benign
lesions unless absolutely necessary [1]. Lund et al's recent
editorial also counselled restraint when considering the
placement of SEMAS for benign lesions [2]. These con-
cerns were based on reports of obstructing granulomas,
mucous plugging, stent fracture, migration, and infection.
Multiple authors have reported such complications [3-6].
In contrast, Thornton and colleagues [7] reported that
with SEMAS, assisted patency rates of nearly 90% could be
achieved, and that SEMAS were well tolerated for years,
and beneficial in patients with selected benign indica-
tions. Husain et al [8] found Ultraflex stents to be both
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safe and effective in the prolonged palliation of benign
airway obstruction.
Concern regarding the potential for stent removal to cause
mucosal tears, haemorrhage, and even pneumothoraces
was also raised. However, Noppen et al [9] found that cov-
ered stents could be removed effectively and safely with-
out major complications.
In view of the differing opinions in the published litera-
ture, we retrospectively reviewed the long-term effects of
SEMAS placed in the airways for benign indications at our
university medical centre over a 10 year period. In partic-
ular, we applied stringent criteria to detect complications
related to metallic stent placement, removal and their seq-
uaelae.
Methods
Data were retrospectively obtained from medical records
of patients who underwent SEMAS placement for the
treatment of non-malignant indications at our institution,
a 577-bed tertiary-care teaching hospital. Patients who
were treated from January 1996 to March 2006 were
included in this review. Patients with malignant airway
obstruction were excluded.
The data collected included patient demographics; indica-
tions for SEMAS placement; comorbidities at presenta-
tion; recorded symptoms of airway obstruction
immediately prior to, within 24 hours of, and between 24
hrs and 12 weeks. Symptoms of airway obstruction were
classified as respiratory distress (including shortness of
breath, progressive dyspnea, respiratory distress, and
hypoxemia), cough, stridor, difficulty clearing secretions,
and obstructive pneumonia. Also noted were elective or
emergent indications for SEMAS placement, broncho-
scopic mode (flexible or FB vs. rigid or RB), broncho-
scopic venue (Intensive Care Unit or ICU, bronchoscopy
suite, or operating room), stent type (covered vs. uncov-
ered), stent brand (Microvasive Ultraflex vs. Wallstent
Endoprosthesis, both by Boston Scientific; Natick, MA)
and size (length and diameter). Complications of SEMAS
treatment and patient mortality were also recorded.
Patient mortality was assessed through a search of our
medical records, the Social Security Death Index, and via
a search of death records by the California Department of
Health Services.
One of two brands of SEMAS was chosen depending on
physician preference and availability. A covered stent was
chosen if the potential for continued granulation tissue
was considered significant. All stents were placed by four
pulmonary and critical care specialists. Patients under-
went flexible or rigid bronchoscopy using conscious seda-
tion or general anesthesia respectively, depending on the
individual patient's clinical status as assessed by the inter-
ventionalist of record. General anesthesia was adminis-
tered during RB utilizing propofol. Conscious sedation
was achieved using fentanyl and midazolam titrated to
effect during FB, in addition to topical lidocaine anesthe-
sia.
The technique for SEMAS removal depended on the extent
of epithelization of the target stent. In the main, an
attempt was made to remove the stent in its entirety if
deemed safe. If, in the opinion of the operator, this was
not feasible, the stent was unraveled or removed piece-
meal, sometimes utilizing an Nd:YAG laser.
Statistical analyses were performed using JMP software
(SAS Institute; Cary, NC). The proportion of complica-
tions associated with stent location, types, and brands
were compared using χ2 or Fisher's exact test. Logistic
regression was employed to determine the significance of
the influence of stent brand and type on complication
rate. Survival was assessed using Kaplan-Meier analysis.
Death from any cause was considered an event, and data
on patients who were alive at the study conclusion were
considered censored. A p-value < 0.05 was considered sig-
nificant. Mean and median statistics are reported ± stand-
ard deviation.
This study was conducted with the approval of our Insti-
tutional Review Board and in compliance with the Health
Insurance Portability and Accountability Act.
Results
During a 10-year period, 35 patients underwent 62 bron-
choscopies resulting in the placement of 82 SEMAS. The
mean number of SEMAS placed per patient was 2.3 ± 1.5,
with a range of 1 to 7. Seventeen patients were female.
Mean patient age was 59.5 ± 14.3 years (range = 28 to 83
years).
All patients were either deemed medically unsuitable for
surgery by the interventionalist or had declined a surgical
solution. Thirty-four (97%) patients had multiple indica-
tions for stent placement (Table 1). The indications most
frequently occurring together were tracheobronchomala-
cia and postintubation stenosis (n = 9 patients). Medical
comorbidities were commonly seen (89% of patients,
Table 2). Presenting symptoms were frequently multiple
(76%) and included symptoms of airway obstruction
(Table 3). Most patients (89%, n = 31) underwent at least
one intervention to treat airway obstruction prior to
SEMAS placement (Table 4).
The majority of SEMAS placement bronchoscopies were
performed in a bronchoscopy suite (71%, n = 44) or ICU
(23%, n = 14), and were elective or non-emergent (92%,BMC Pulmonary Medicine 2008, 8:7 http://www.biomedcentral.com/1471-2466/8/7
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n = 57). Of 5 emergent bronchoscopies, 4 were performed
in the ICU. Another 4 bronchoscopies (6%) were per-
formed in the operating room, utilizing RB in three. Of 59
FB's, 53 (90%) were performed using conscious sedation.
Fifty-five of 82 (67%) SEMAS were Ultraflex, and 69% of
these were uncovered. Of 27 Wallstents used, 59% (n =
16) were uncovered. Mean SEMAS length was 40 ± 10.6
mm (range = 20–60 mm), and mean diameter was 16 ±
3.3 mm (range = 8–22 mm).
SEMAS were most frequently deployed in the trachea
(68% of stents, n = 56), and were mainly proximal or sub-
glottic (40%, n = 33) (Table 5). Eighty percent of patients
(n = 28) underwent additional interventions post airway
stent placement to treat SEMAS-related complications or
as part of a surveillance protocol (Table 6).
Symptomatic improvement within 24 hours of stent
placement was noted in 83% of patients. In particular,
stridor (73% of cases); respiratory distress (71%); cough
(79%); and difficulty clearing secretions (75%) were
noted to have resolved or improved.
The mean time to first repeat bronchoscopy post SEMAS
placement was 173 ± 267 days (median = 37 days), with
a mean number of additional therapeutic bronchoscopies
of 4.3 ± 2.9 (median = 4 interventions).
Overall, 80% of patients (n = 28) experienced one or more
complications. A total of 172 complications were
observed. Complications were categorized as early (occur-
ring within 24 hours post stent placement) and late
(occurring > 24 hours post stent placement), and also as
major and minor. Major complications were defined as
those requiring an intervention or having a significant
clinical impact. Minor complications were defined as
those not necessarily requiring an intervention or having
significant clinical impact. Forty-six percent of patients (n
= 16) experienced at least one major complication and
77% (n = 27) experienced one or more minor complica-
tions.
Early complications
Three patients (9%) experienced major complications:
one patient who had received laser phototherapy immedi-
ately prior to stent placement developed stridor from glot-
tic edema requiring temporary intubation for resolution
several hours after the procedure; another experienced
sustained desaturation to 83% and persistent cough
which resolved after 3 hours of continuous positive air-
way pressure (CPAP) therapy and nebulized albuterol
Table 1: Indications for SEMAS placement
n (patients) % total patients
Tracheobronchomalacia 23 65.7
Postintubation stenosis 17 48.6
Lung transplant anastomosis stenosis 4 11.4
Tuberculosis or mucormycosis scarring 3 8.6
Radiotherapy changes 25 . 7
Localized cartilaginous hypertrophy 1 2.9
Wegner's granulomatosis 12 . 9
Bronchial necrosis due to foreign matter aspiration 1 2.9
Table 2: Comorbidities at presentation.*
n (patients) % total patients
Chronic obstructive pulmonary disease 14 40.0
Pneumonia 10 28.6
Lung transplant 41 1 . 4
Interstitial lung disease 4 11.4
Cerebro-vascular accident 3 8.6
Adult respiratory distress syndrome 2 5.7
Other infection (non-respiratory) 2 5.7
Congestive heart failure 2 5.7
Other malignancy 12 . 9
Collage-Vascular Disease 1 2.9
Immunocompromised 1 2.9
Critical illness neuromyopathy 1 2.9
*Patients may have had more than 1 comorbidity. Comorbidities were observed in 89% (n = 31) of patients.BMC Pulmonary Medicine 2008, 8:7 http://www.biomedcentral.com/1471-2466/8/7
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treatments. In the third patient, a single stent migrated
distally requiring removal and replacement with a silicone
stent (Dumon, Novatech, La Ciotat, France).
Late complications
Late complications occurred in over three-fourths (77%)
of patients; with major complications occurring in 37% (n
= 13) of patients, and minor complications in 77% of
patients (n = 27) (Table 7). Overall, granulation tissue for-
mation (obstructive or non-obstructive) at the site of the
SEMAS was observed in 57% (n = 20) of patients, and was
significantly higher in tracheal (59%, n = 33 of 56) than
in bronchial (34%, n = 9 of 26) stents (p = 0.040).
Progressive dyspnoea occurred in 11 (31.4%) patients
>24 hrs post stent placement; but were assessed to have
been related to the patients' comorbidities. Neither airway
perforation nor fistula formation complicated SEMAS
placement.
No significant difference in complications or survival was
observed between stent types. However, Wallstents were
associated with a significantly higher proportion of late
complications compared to Ultraflex SEMAS, in particu-
lar, bleeding (30% vs. 5%, P = 0.005) and migration (26%
vs. 7%, P = 0.026).
Median length of patient follow-up post SEMAS place-
ment was 473 ± 654 days (mean = 623.5 days). The
majority of in-situ stents (88%) as of last known patient
follow-up, had remained in the airways for a mean of 616
± 654 days (range = 1 to 3205 days).
Removal of 12 SEMAS was attempted in 4 patients; 10
were successfully removed. Indications for removal
included stent fracture (n = 6), migration (n = 5), granu-
lation tissue (n = 4), mucous plugging/obstruction (n =
4), recurrence of stenosis (n = 3), no clinical improvement
(n = 3), and hemoptysis (n = 1). Both stents that could not
be removed were uncovered; one was a Wallstent, the
other an Ultraflex stent. In one patient, a stent was too
deeply embedded in the endotracheal mucosa for safe
removal. In another, a single stent could not be removed
despite manipulation. This patient subsequently expired
from causes unrelated to stent placement. Nine of 10
(90%) stent removals were uncomplicated. The single
complication observed was the retention of a fractured
stent wire that was too deeply embedded in the mucosa.
Half of the 12 SEMAS selected for removal were covered.
Four were Wallstents, and 8 were Ultraflex. The longest
indwelling stent removed had been in place for 3.8 years.
Twenty patients (57%) were alive up to the date of this
review (April 2007). Median survival post initial SEMAS
placement was 3.6 ± 2.7 years, range 10 days to 10.3 years.
While no deaths could be directly attributed to the airway
stents, the exact cause of death for 8 subjects in this review
could not be determined despite strong data collection
efforts. Thus, it is possible that the death rate in this series
may be as high as 23% (8 of 35 patients). The median sur-
vival time of patients for whom cause of death could not
be determined was 2.4 ± 1.2 years.
Discussion
Patients with benign stenotic airways disease should be
considered for surgical intervention [3]. We have, how-
Table 3: Symptoms of airway obstruction at presentation.
n (patients) % total patients
Respiratory distress 29 82.9
Cough 17 48.6
Stridor 14 40.0
Difficulty clearing secretions 13 37.1
Obstruction pneumonia 1 2.9
Table 4: Therapeutic interventions prior to SEMAS placement
n (patients undergoing intervention) % of 31 patients undergoing at least 1 intervention
Laser resection (Nd:YAG, KTP, or CO2) 24 77.4
Balloon dilatation 16 51.6
Silicone stent placement 5 16.1
Tracheostomy tube placement 4 12.9
Bronchoscopic debridement 2 6.5
Table 5: Stent deployment location.
n (stents) % total stents
Proximal trachea/subglottic 33 40.2
Mid trachea 11 13.4
Distal trachea 12 14.6
Left main bronchus 17 20.7
Right main bronchus 6 7.3
Right broncus intermedius 3 3.7
Proximal trachea = upper third, mid-trachea = middle third, distal 
trachea = lower third.BMC Pulmonary Medicine 2008, 8:7 http://www.biomedcentral.com/1471-2466/8/7
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ever, focused in this 10 year retrospective study on a
cohort of 35 patients with benign airway lesions who were
not surgical candidates because of significant medical
comorbidities (88%), or because they declined surgery.
While the majority of our stents (n = 77, 91%) were
placed prior to the FDA's Public Health Notification [1],
we suggest that similar groups of highly selected patients
may benefit from SEMAS placement [8] Indeed, most
(90%) of our patients had undergone an interventional
bronchoscopic procedure prior to stent placement,
mainly laser phototherapy (77%), and/or balloon dilata-
tion (52%), consistent with the acuity and severity of their
disease. Ninety-seven percent were symptomatic, 4
required prior temporizing tracheostomy tube placement,
and another five required SEMAS to replace silicone stents
(Dumon) that had mostly migrated.
SEMAS placement was highly effective, affording sympto-
matic improvement in 83% of patients within 24 hours.
In particular respiratory distress/stridor and cough were
alleviated after a mean of 2.3 stents were placed in each
patient. These results are supported by other authors
[7,10].
While the majority (94%) of our stents were placed using
FB and conscious sedation, only 5% were placed using RB
because of the patients' clinical status, operator prefer-
ence, and logistic issues. Utilisation of the FB for metallic
stent placement appears to be a safe method under these
circumstances [11], with 68% of stents in our series being
placed in the trachea, especially proximally, and, 21% in
the left main bronchus.
The use of silicone stents in benign disease does not
appear to be as controversial as that of SEMAS [12]. Nev-
ertheless, we chose SEMAS over silicone stents because of
a superior inner diameter to wall thickness ratio [8,13],
and potentially fewer problems with stent migration
[10,14,15] and airway obstruction due to secretions[16].
Some of our patients were deemed medically unsuitable
for general anaesthesia and hence RB by the intervention-
alist of record. Silicone stents are easily removed after
placement, even several years later [17], but as Walser [18]
suggests, they have a potential for migration in up to 28%
of cases. In addition, Grewe et al [19] found that airway
non-covered metal stents may be utilized long-term for
nonmalignant obstructive disease, and that no malignant
Table 6: Additional interventions post SEMAS placement:
N (patients) % of 28 patients undergoing at least one 
intervention post metallic stent placement
Range (# procedures per patient)
Repeat bronchoscopy (unrelated to 
procedures below)
27 96.4 0–13
Laser resection 12 42.9 0–4
Balloon dilation 4 14.3 0–4
Tracheostomy tube placement 1 3.6 0–1
Debridement of granulation tissue 1 3.6 0–1
Silicone stent placement after failure of 
metallic stent
1 3.6 0–1
Table 7: Complications occurring >24 hrs post stent placement*:
n (stents associated with complication) % total stents n (patients) % total pts
Major complications
Obstructive granuloma 20 24.4 10 28.6
Stent fracture 16 19.5 6 17.1
Stent migration 10 12.2 6 17.1
Minor complications
Impaired secretion clearance 34 41.5 17 48.6
Granulation tissue formation overlying stent 13 15.8 13 37.1
Infection (local or pneumonia) 17 20.7 8 22.9
Bleeding (not requiring transfusion) 11 13.4 6 17.1
Persistent cough 10 12.2 6 17.1
Stent compression or misshaping 4 11.5 4 11.4
Disease recurrence at stent site 6 7.3 3 8.6
*More than one complication may have occurred per patient.BMC Pulmonary Medicine 2008, 8:7 http://www.biomedcentral.com/1471-2466/8/7
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transformation of previously non-tumorous tissue
occurred.
No patient in our series was complicated by airway perfo-
ration or tracheo-oesophageal fistulae resulting from
SEMAS placement. Initial technical success in reference to
metallic stent placement was 100%. However, during the
first 24 hours post initial stent placement, three patients
(9 %) experienced major reversible complications that
were ultimately resolved by additional interventions. The
immediate complication rate appears similar to that of
Thornton et al [7].
Late complications occurred in 77% of our patients, with
this figure reflecting relatively minor complications in 27
patients. However, 13 patients, (37%) experienced major
complications, mainly because of stent migration and/or
fracture, or for treatment of obstructive granulomas. In
comparison, a total of 28 patients (80%) required an
interventional procedure after SEMAS placement that was
not necessarily related to complications from SEMAS. This
higher proportion of patients likely reflects the course of
the patients' disease process, especially in terms of
impaired mucous clearance. The time to first repeat bron-
choscopy was highly variable, again likely reflecting the
individual patient's disease course, with a mean of 6
months. A majority (88%) of SEMAS remained in-situ as
of last known patient follow-up, representing a mean of
23.8 ± 21.8 months.
Although Saad et al [16] found no difference in complica-
tion rates between Wallstent and Ultraflex stents, or cov-
ered and uncovered ones; our series found that Wallstents
were associated with a significantly higher incidence of
bleeding and migration. While the explanation for this is
unclear, and may be related to the individual patient's
anatomy and disease process, the somewhat different
structures of both stents are noted. These complications,
however, were only observed in 13% of stents. Rieger et al
[20] found that Wallstents led to the formation of granu-
lomas that required frequent intervention. While granula-
tion tissue did occur in all our stent types, no significant
difference was found in its incidence amongst the stent
categories. Our finding of granulation tissue in 57% of
patients is greater than that reported by Saad et al for
benign conditions (33.3%) [16]. Apart from individual
patient differences especially in terms of bronchial
mucosal inflammation, our longer median follow up of
473 days vs. 336 days may have also contributed to the
higher figure. We did note however that 40% of our stents
had been placed in the proximal/subglottic trachea, where
16 of 20 (80%) patients developed granulomas. Based on
this result, we agree that the placement of stents in the
proximal/subglottic trachea should be avoided if at all
possible.
While we have included Wallstents in this retrospective, it
is important to note that the manufacturer of this type of
stent does not now recommend their use in the airways.
Several authors have suggested that removal of metallic
airway stents are ideally performed using RB and general
anaesthesia [9,21], or using a combined open and endo-
scopic approach [22]. Our data suggest that suitably
selected patients can safely undergo SEMAS removal uti-
lizing a FB. This appears similar to Thornton et al's [7]
findings where the authors did not use RB for successful
stent removal. Of the two SEMAS that could not be
removed in our study, only one was deemed too risky to
be removed. Nevertheless, we agree with Noppen et al [9]
that under certain circumstances the removal of SEMAS
that has established in the airway mucosa can be very haz-
ardous, requiring much forethought prior to removal.
Our study is limited by its retrospective nature and is best
viewed as a single tertiary referral centre's experience in
managing a cohort of highly symptomatic and ill patients.
Surgical reconstruction, especially of the trachea, can be
technically challenging, and may of itself lead to anasto-
motic dehiscence and re-stenoses [23]. Kabbani et al [23]
suggest that stent placement can be an attractive alterna-
tive even in benign airway obstruction for these reasons.
The exact indications for stent placement in benign stric-
tures are still being emotionally debated amongst pulmo-
nologists and surgeons [24], appear institution specific,
but at least include airway compression from benign thy-
roid disease [25] and strictures from transplantation anas-
tomoses [26].
Of interest, all mortalities in this series occurred within
3.5 years of stent placement. This finding may reflect the
significant co-existing medical morbidities in our patient
cohort. Although we have attributed the deaths of 8 of
those patients to complications resulting from SEMAS
placement, this was done by convention because of lack of
available data as to their actual cause of death.
Comparison to other series is difficult not least because of
differing patient pathologies and their severities
[7,16,27]. Madden et al [3] reported that 48% of their
patients had at least one if not more large airway compli-
cations from Ultraflex stent placement, with granulation
tissue occurring in 35% of patients. In our series, 80% of
stents, representing 80% of patients, were linked to at
least one complication. While very rigorous and inclusive
in our data collection, we found that major complica-
tions, although associated with 37% (n = 30) of stents in
46% of patients, were largely reversible. Nevertheless, we
agree with other authors [2,3,7,16,20,28] that other surgi-
cal and medical therapeutic options should be first con-
sidered, including perhaps non-invasive positive pressureBMC Pulmonary Medicine 2008, 8:7 http://www.biomedcentral.com/1471-2466/8/7
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ventilation. Stent placement was the last resort in our
patient cohort to effectively relieve symptoms. Certainly,
silicone stents are currently reported to be preferable to
SEMAS for benign lesions, and need to be strongly consid-
ered. However, neither silicone stents nor SEMAS are
ideal, and some patients would not have been able to tol-
erate general anaesthesia for RB. Emad [29] suggests that
the ideal stent in the future would be made of a biocom-
patible material that maintains mucociliary clearance and
minimizes granulation tissue formation. Saito et al [30]
report on a new tubular bioabsorbable stent made of
poly-L-lactic acid in the rabbit model, and Zakaluzny et al
[31] discuss drug-eluting stents to inhibit granulation tis-
sue. Together with improved techniques in the stent inser-
tion and removal, and possibly surveillance
bronchoscopies, morbidity and mortality may be mini-
mized [16].
Conclusion
As there is no available randomized trial comparing types
of stents, or treated and untreated patients [24], strong
consideration should be given towards the establishment
of at least a national, if not international database of
patients undergoing airway stent placement for benign
lesions. Analysis of this database may well allow us to not
only to establish clinical indications, patient treatment
pathways [32] and stent choice and techniques, but also
to ultimately maximize treatment efficacy in this unfortu-
nate group of patients.
Nevertheless, in the meantime, SEMAS could be consid-
ered as a therapeutic option for inoperable central airway
lesions, especially in patients with medical co-morbidi-
ties. However, in light of the complication rate observed
in this series overall, careful consideration should be
given to their use, as treatment with SEMAS may necessi-
tate lifelong follow-up and visual surveillance of the
SEMAS as clinically indicated.
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